Pharma BD Deal Intelligence
Servier's 2006 acquisition of Symphogen bought a leading antibody discovery company outright, betting on recombinant antibody-mixture capability for its oncology pipeline—though the announcement itself disclosed no price or pipeline specifics to judge the bet by.
Servier acquires Symphogen gaining Danish biotech antibody discovery capabilities for recombinant antibody mixtures in oncology pipeline
Servier completes acquisition of Symphogen gaining next-generation antibody technologies and pipeline of oncology therapeutic candidates
Servier completes the acquisition of Symphogen establishing antibody center of excellence for oncology and immuno-oncology development
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Servier acquired Symphogen, a leading antibody discovery company.
Servier SA completed its acquisition of Symphogen A/S. Servier acquired Symphogen, a leading antibody discovery company.
Servier SA completed this transaction with Symphogen A/S. Assessment based on available records.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Servier / Symphogen A/S (this deal) | 2006 | — | 66 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| Servier / Edgewise Therapeutics, Inc. | 2026 | $2.6B | 75 |
| Servier / Aitia | 2024 | — | — |
| Servier / AmoyDx | 2024 | — | — |
| Servier / kyron.bio | 2026 | — | — |
← Browse all deals · How we score deals
More: 2006 deals · Servier deals · Oncology deals